Publications by authors named "Jonathan Fitzgerald"

Claim this Profile
A
An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release.
Miguel Gaspar, Marina Natoli, Laure Castan, Sharif Rahmy, Martin Korade, Jonathan Fitzgerald

J Immunother Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel.
Christina M Scribano, Jun Wan, Karla Esbona, John B Tucker, Amber Lasek, Jonathan Fitzgerald

Sci Transl Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Longitudinal PET Imaging to Monitor Treatment Efficacy by Liposomal Irinotecan in Orthotopic Patient-Derived Pancreatic Tumor Models of High and Low Hypoxia.
Manuela Ventura, Nicholas Bernards, Raquel De Souza, Inga B Fricke, Bart S Hendriks, Jonathan B Fitzgerald

Mol Imaging Biol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal PET Imaging to Monitor Treatment Efficacy by Liposomal Irinotecan in Orthotopic Patient-Derived Pancreatic Tumor Models of High and Low Hypoxia.
Manuela Ventura, Nicholas Bernards, Raquel De Souza, Inga B Fricke, Bart S Hendriks, Jonathan B Fitzgerald

Mol Imaging Biol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Companion Diagnostic Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines.
Helen Lee, Daniel Gaddy, Manuela Ventura, Nicholas Bernards, Raquel de Souza, Jonathan Fitzgerald

Theranostics· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis.
Nicholas Bernards, Manuela Ventura, Inga B Fricke, Bart S Hendriks, Jonathan Fitzgerald

Mol Pharm· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery.
Huang-Chiao Huang, Imran Rizvi, Joyce Liu, Sriram Anbil, Ashish Kalra, Jonathan Fitzgerald

Cancer Res· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Shannon C Leonard, Helen Lee, Daniel F Gaddy, Stephan G Klinz, Nancy Paz, Jonathan B Fitzgerald

Anticancer Drugs· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study.
Ramesh K Ramanathan, Ronald L Korn, Natarajan Raghunand, Jasgit C Sachdev, Ronald G Newbold, Jonathan B Fitzgerald

Clin Cancer Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
Jennifer L Clarke, Annette M Molinaro, Juan R Cabrera, Ashley A DeSilva, Jane E Rabbitt, Jonathan B Fitzgerald

Cancer Chemother Pharmacol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
Birgit Schoeberl, Art Kudla, Kristina Masson, Ashish Kalra, Michael Curley, Jonathan Fitzgerald

NPJ Syst Biol Appl· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal tumor hypoxia imaging with [(18)F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity.
Jinzi Zheng, Stephan G Klinz, Raquel De Souza, Jonathan Fitzgerald, David A Jaffray

EJNMMI Res· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
Jeffrey D Kearns, Raghida Bukhalid, Mark Sevecka, Gege Tan, Nastaran Gerami-Moayed, Jonathan B Fitzgerald

Mol Cancer Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
Min H Kang, Jing Wang, Monish R Makena, Joo-Sang Lee, Nancy Paz, Jonathan B Fitzgerald

Clin Cancer Res· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resolution of inflammation is altered in Alzheimer's disease.
Xiuzhe Wang, Mingqin Zhu, Erik Hjorth, Veronica Cortés-Toro, Helga Eyjolfsdottir, Jonathan M Fitzgerald

Alzheimers Dement· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Ashish V Kalra, Jaeyeon Kim, Stephan G Klinz, Nancy Paz, Jason Cain, Jonathan B Fitzgerald

Cancer Res· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.
Jonathan B Fitzgerald, Bryan W Johnson, Jason Baum, Sharlene Adams, Sergio Iadevaia

Mol Cancer Ther· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid optimization and prototyping for therapeutic antibody-like molecules.
Lihui Xu, Neeraj Kohli, Rachel Rennard, Yang Jiao, Maja Razlog, Jonathan Fitzgerald

MAbs· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous fish oil lipid emulsion promotes a shift toward anti-inflammatory proresolving lipid mediators.
Brian T Kalish, Hau D Le, Jonathan M Fitzgerald, Samantha Wang, Kyle Seamon

Am J Physiol Gastrointest Liver Physiol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contributions of the three CYP1 monooxygenases to pro-inflammatory and inflammation-resolution lipid mediator pathways.
Senad Divanovic, Jesmond Dalli, Lucia F Jorge-Nebert, Leah M Flick, Marina Gálvez-Peralta, Jonathan M Fitzgerald

J Immunol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury.
Takuya Miyahara, Sara Runge, Anuran Chatterjee, Mian Chen, Giorgio Mottola, Jonathan M Fitzgerald

FASEB J· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
Pin-Yuan Chen, Tomoko Ozawa, Daryl C Drummond, Ashish Kalra, Jonathan B Fitzgerald

Neuro Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypothyroidism presenting with recurrent pericardial tamponade.
Stephen Arthur, Gailash Beeharry-Panray, Jonathan Fitzgerald, Ian Loke

BMJ Case Rep· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational engineering of antibody therapeutics targeting multiple oncogene pathways.
Jonathan Fitzgerald, Alexey Lugovskoy

MAbs· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.
Birgit Schoeberl, Emily A Pace, Jonathan B Fitzgerald, Brian D Harms, Lihui Xu

Sci Signal· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis